HRP20180016T1 - Postupci primjene egfr-inhibitora - Google Patents

Postupci primjene egfr-inhibitora Download PDF

Info

Publication number
HRP20180016T1
HRP20180016T1 HRP20180016TT HRP20180016T HRP20180016T1 HR P20180016 T1 HRP20180016 T1 HR P20180016T1 HR P20180016T T HRP20180016T T HR P20180016TT HR P20180016 T HRP20180016 T HR P20180016T HR P20180016 T1 HRP20180016 T1 HR P20180016T1
Authority
HR
Croatia
Prior art keywords
bibw
pharmaceutically acceptable
acceptable salt
inhibitor
patient
Prior art date
Application number
HRP20180016TT
Other languages
English (en)
Croatian (hr)
Inventor
Robert Michael Lorence
Mehdi Shahidi
Peter Stopfer
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44583460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20180016(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of HRP20180016T1 publication Critical patent/HRP20180016T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/5758—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
HRP20180016TT 2010-08-26 2011-08-24 Postupci primjene egfr-inhibitora HRP20180016T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37717710P 2010-08-26 2010-08-26
EP11752700.2A EP2608792B1 (en) 2010-08-26 2011-08-24 Methods of administering an egfr inhibitor
PCT/US2011/048922 WO2012027445A1 (en) 2010-08-26 2011-08-24 Methods of administering an egfr inhibitor

Publications (1)

Publication Number Publication Date
HRP20180016T1 true HRP20180016T1 (hr) 2018-02-09

Family

ID=44583460

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180016TT HRP20180016T1 (hr) 2010-08-26 2011-08-24 Postupci primjene egfr-inhibitora

Country Status (16)

Country Link
US (2) US20130289056A1 (show.php)
EP (1) EP2608792B1 (show.php)
JP (3) JP2013536244A (show.php)
CY (1) CY1119898T1 (show.php)
DK (1) DK2608792T3 (show.php)
EC (1) ECSP13012523A (show.php)
ES (1) ES2655115T3 (show.php)
HR (1) HRP20180016T1 (show.php)
HU (1) HUE038049T2 (show.php)
LT (1) LT2608792T (show.php)
NO (1) NO2608792T3 (show.php)
PL (1) PL2608792T3 (show.php)
PT (1) PT2608792T (show.php)
RS (1) RS56682B1 (show.php)
SI (1) SI2608792T1 (show.php)
WO (1) WO2012027445A1 (show.php)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2972135T3 (es) 2008-10-02 2024-06-11 Salix Pharmaceuticals Inc Tratamiento de encefalopatía hepática usando rifaximina
NO2608792T3 (show.php) * 2010-08-26 2018-03-10
CN113164440A (zh) * 2018-11-30 2021-07-23 贝斯以色列女执事医疗中心有限公司 减少癌症患者的主要血栓事件的组合物和方法
WO2022243942A1 (en) 2021-05-19 2022-11-24 Quercis Pharma AG Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis
WO2023288044A1 (en) 2021-07-16 2023-01-19 Beth Israel Deaconess Medical Center, Inc. Method for treating sickle cell disease using quercetin-containing compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
WO2002087585A1 (en) * 2001-05-01 2002-11-07 Abbott Laboratories Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
US20030225079A1 (en) 2002-05-11 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
DE10307165A1 (de) 2003-02-20 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20070009533A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
US20090306101A1 (en) * 2005-11-11 2009-12-10 Flavio Solca Combination treatment of cancer comprising egfr/her2 inhibitors
CA2833706C (en) * 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
SI1981863T1 (sl) 2006-01-26 2013-01-31 Boehringer Ingelheim International Gmbh Postopek za pripravo aminokrotonilamino-substituiranih kinazolinskih derivatov
EP2068880B1 (en) 2006-09-18 2012-04-11 Boehringer Ingelheim International GmbH Method for treating cancer harboring egfr mutations
WO2008121467A2 (en) 2007-02-28 2008-10-09 Dana-Farber Cancer Institute, Inc. Combination therapy for treating cancer
UY31867A (es) 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
HRP20191005T1 (hr) 2009-07-06 2019-08-23 Boehringer Ingelheim International Gmbh Postupak sušenja bibw2992, njegovih soli i čvrstih farmaceutskih formulacija koje sadrže taj djelatni sastojak
NO2608792T3 (show.php) 2010-08-26 2018-03-10

Also Published As

Publication number Publication date
ECSP13012523A (es) 2013-05-31
JP2017081966A (ja) 2017-05-18
CY1119898T1 (el) 2018-06-27
LT2608792T (lt) 2018-01-10
EP2608792A1 (en) 2013-07-03
US20130289056A1 (en) 2013-10-31
JP6541637B2 (ja) 2019-07-10
WO2012027445A1 (en) 2012-03-01
RS56682B1 (sr) 2018-03-30
NO2608792T3 (show.php) 2018-03-10
ES2655115T3 (es) 2018-02-16
US20160287591A1 (en) 2016-10-06
PT2608792T (pt) 2018-01-15
JP2019147814A (ja) 2019-09-05
SI2608792T1 (en) 2018-02-28
DK2608792T3 (en) 2018-01-15
EP2608792B1 (en) 2017-10-11
HUE038049T2 (hu) 2018-09-28
PL2608792T3 (pl) 2018-03-30
JP2013536244A (ja) 2013-09-19

Similar Documents

Publication Publication Date Title
Kishimoto et al. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories
JP7083330B2 (ja) 下部尿路症状、良性前立腺過形成、勃起障害の治療に有用な組成物及び方法
ES2368066T3 (es) Comprimido de liberación retardada con geometría de nucleo definida.
HRP20180016T1 (hr) Postupci primjene egfr-inhibitora
ES2904570T3 (es) Formulación de DHE intranasal para el tratamiento del dolor de cabeza
Ettl Management of adverse events due to cyclin-dependent kinase 4/6 inhibitors
Oberoi et al. A phase 1 study to evaluate the effect of crushing, cutting into half, or grinding of glecaprevir/pibrentasvir tablets on exposures in healthy subjects
Vidlar et al. The safety and efficacy of a silymarin and selenium combination in men after radical prostatectomy-a six month placebo-controlled double-blind clinical trial
BR112012000862A8 (pt) composição farmacêutica oral, composição farmacêutica oral de baixa dose para administração crônica, método de tratamento ou retardo do inicio ou desenvolvimento de uma condição, método de tratamento da dor em um indivíduo que necessita deste medicamento, método de tratamento de uma condição em um indivíduo que necessita deste medicamento
CN118557737A (zh) 治疗胃肠道间质瘤的组合疗法
Zou et al. Protective effects of Lepidium meyenii (Maca) aqueous extract and lycopene on testosterone propionate‐induced prostatic hyperplasia in mice
van Ryn et al. The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation
JP2024533756A (ja) アトゲパントを含む片頭痛の併用療法
Azanza et al. Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences
AU2023244611A1 (en) Methods and bioavailable highly permeable compounds for the treatment of viral diseases
Scherf-Clavel Drug–drug interactions with over-the-counter medicines: Mind the Unprescribed
Dayrit et al. Philippine medicinal plants with potential immunomodulatory and anti-SARS-CoV-2 activities
Jungbauer et al. The frequency of prescription of P‐glycoprotein‐affecting drugs in atrial fibrillation
ES2741774T3 (es) Terapia complementaria para la hiperplasia prostática benigna
Oga et al. Ex vivo and in vivo investigations of the effects of extracts of Vernonia amygdalina, Carica papaya and Tapinanthus sessilifolius on digoxin transport and pharmacokinetics: assessing the significance on rat intestinal P-glycoprotein efflux
Rodrigues et al. Preventive and therapeutic anti-inflammatory effects of systemic and topical thalidomide on endotoxin-induced uveitis in rats
KR102211313B1 (ko) 울금 및 정향의 혼합 추출물을 포함하는 전립선비대증의 예방 또는 치료용 조성물
CN117979991A (zh) 使用药物和疫苗接种组合治疗的用于治疗、改善或预防感染的方法
Sheikh et al. Hay fever in adolescents and adults
WO2015092123A1 (en) Compositions comprising glycerophosphorylethanolamine